Latest News

In this article by International Biopharmaceutical Industry, Martin Wing-King, VP and General Manager, Site Head at our Reading facility, explores the demand for accelerated first-in-human trials and outlines how simple formulations can be ...

Quotient Sciences is pleased to announce that its Chief Scientific Officer, Dr. Andy Lewis, has joined the scientific advisory board for a new journal by the Royal Society of Chemistry – RSC Pharmaceutics.

NOTTINGHAM, UK, ENCINITAS, CA; September 10, 2024 – VS-041, a novel and potentially life-saving treatment for heart failure, developed by Vasa Therapeutics, a San Diego-based biotechnology company, has reached a major clinical milestone wit...

In this article by Pharma Focus, Dr. Andrew Lewis, the Chief Scientific Officer at Quotient Sciences discusses the efficiency of oral peptides and their attractiveness as a drug candidate. "Continued advancements in drug deliv...

In the rapidly evolving bio/pharmaceutical industry, integrating advanced technologies and patient-centric strategies is crucial for formulation success. This article by Pharma Tech explores how digitalization, artificial intelligence (AI),...